/PRNewswire/ The "Respiratory Inhalers: Global Strategic Business Report" report has been added to ResearchAndMarkets.com s offering. The global market for.
Edesa Biotech Inc (NASDAQ: EDSA) released findings from an in vitro study involving its monoclonal antibody candidate, paridiprubart. The study, conducted by the University of Toronto, ran parallel to Edesa's ongoing clinical study of EB05 (paridiprubart) in hospitalized Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS), a severe form of respiratory failure characterized by extensive inflammatory damage to the lungs. The preprint research results revealed demonstrate that various
ARDS is a lung condition where the patient suffers from sudden breathlessness, low blood oxygen levels and lung inflammation that could progress to respiratory failure.